Secondary sideroblastic anemia due to drugs and toxins
ICD-10 D64.2 is a billable code used to indicate a diagnosis of secondary sideroblastic anemia due to drugs and toxins.
Secondary sideroblastic anemia is a type of anemia characterized by the presence of ringed sideroblasts in the bone marrow, which are erythroblasts that contain iron granules. This condition arises as a result of exposure to certain drugs and toxins that interfere with hemoglobin synthesis. Common culprits include alcohol, lead, and various chemotherapeutic agents. Patients may present with symptoms of anemia such as fatigue, pallor, and shortness of breath. The diagnosis is confirmed through a combination of clinical evaluation, blood tests showing microcytic anemia, and a bone marrow biopsy revealing the characteristic sideroblasts. Treatment focuses on removing the offending agent and may include supportive care such as blood transfusions or iron chelation therapy if iron overload occurs. Understanding the underlying cause is crucial for effective management and prevention of further complications.
Detailed patient history including medication use, laboratory results, and bone marrow biopsy findings.
Patients presenting with unexplained anemia and a history of drug exposure.
Ensure all relevant lab results and treatment plans are documented to support the diagnosis.
Documentation of chemotherapy regimens and any associated toxicities.
Patients undergoing treatment for malignancies who develop anemia.
Monitor for potential drug interactions and cumulative toxicity.
Used to evaluate anemia and monitor treatment response.
Document the reason for the CBC and any relevant findings.
Hematology specialists should ensure all relevant lab results are included.
Common causes include exposure to certain drugs (like chloramphenicol, isoniazid), toxins (like lead), and alcohol abuse. Identifying the specific cause is crucial for treatment.
